المؤلفون: Warnick JA; Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania, USA., Gifeisman RI; Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania, USA., Joshi KP; Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania, USA., Roe SA; Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania, USA., Hiciano RA; Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania, USA., Conroy CP; Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania, USA., Zahedi S; Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania, USA.; Centurion Health, State Correctional Institution, Waymart, Pennsylvania, USA.; University of Connecticut School of Medicine, Farmington, Connecticut, USA.

المصدر: Journal of correctional health care : the official journal of the National Commission on Correctional Health Care [J Correct Health Care] 2024 Jun; Vol. 30 (3), pp. 167-171. Date of Electronic Publication: 2024 Apr 01.

نوع المنشور: Journal Article; Case Reports; Review

بيانات الدورية: Publisher: Mary Ann Liebert Country of Publication: United States NLM ID: 9503759 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1940-5200 (Electronic) Linking ISSN: 10783458 NLM ISO Abbreviation: J Correct Health Care Subsets: MEDLINE

مواضيع طبية MeSH: Antipsychotic Agents*/therapeutic use , Antipsychotic Agents*/administration & dosage , Aripiprazole*/therapeutic use , Aripiprazole*/administration & dosage , Schizophrenia, Treatment-Resistant*/drug therapy, Humans ; Male ; Adult ; Drug Therapy, Combination ; Citalopram/therapeutic use ; Citalopram/administration & dosage ; Paliperidone Palmitate/administration & dosage ; Paliperidone Palmitate/therapeutic use ; Schizophrenia/drug therapy ; Correctional Facilities ; Clozapine/therapeutic use ; Clozapine/administration & dosage

المؤلفون: Chen LC; Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts., Ogbutor C; Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts., Kelley KJ; Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts., Senna MM; Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts; Department of Dermatology, Harvard Medical School, Boston, Massachusetts. Electronic address: Maryanne.M.Senna@lahey.org.

المصدر: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Jun; Vol. 90 (6), pp. 1260-1262. Date of Electronic Publication: 2024 Feb 02.

نوع المنشور: Letter; Journal Article

بيانات الدورية: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE

مواضيع طبية MeSH: Alopecia*/drug therapy , Lichen Planus*/drug therapy , Lichen Planus*/pathology , Pyrimidines*/administration & dosage , Pyrimidines*/therapeutic use , Piperidines*/administration & dosage , Piperidines*/therapeutic use, Humans ; Female ; Middle Aged ; Male ; Fibrosis ; Aged ; Adult ; Treatment Outcome ; Pyrroles/administration & dosage ; Pyrroles/therapeutic use ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/therapeutic use ; Administration, Topical

المؤلفون: Suzuki Y; Department of Pharmacy, Ibaraki Prefectural Central Hospital, Koibuchi 6528, Kasama, Ibaraki, 309-1973, Japan. ysuzu-tuk@umin.ac.jp., Ishiguro S; Department of Medical Oncology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan., Shimada H; Department of Pharmacy, Ibaraki Prefectural Central Hospital, Koibuchi 6528, Kasama, Ibaraki, 309-1973, Japan., Ohgami M; Department of Pharmacy, Ibaraki Prefectural Central Hospital, Koibuchi 6528, Kasama, Ibaraki, 309-1973, Japan., Suzuki M; Department of Pharmacy, Ibaraki Prefectural Central Hospital, Koibuchi 6528, Kasama, Ibaraki, 309-1973, Japan.

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 Jun; Vol. 93 (6), pp. 633-638. Date of Electronic Publication: 2023 Dec 26.

نوع المنشور: Case Reports; Journal Article

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Nivolumab*/adverse effects , Nivolumab*/administration & dosage , Mycophenolic Acid*/administration & dosage , Mycophenolic Acid*/adverse effects , Ipilimumab*/adverse effects , Ipilimumab*/administration & dosage , Melanoma*/drug therapy , Chemical and Drug Induced Liver Injury*/etiology, Humans ; Male ; Aged ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/administration & dosage ; Drug Monitoring/methods

المؤلفون: Watanabe M; Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Takao C; Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Maeda C; Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Nayanar G; Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Tominaga R; Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Kimura Y; Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Tu TTH; Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.; Department of Basic Dental Sciences, Faculty of Odonto-stomatology, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam., Nagamine T; Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.; Department of Psychiatric Internal Medicine, Sunlight Brain Research Center, Yamaguchi, Japan., Toyofuku A; Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

المصدر: Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Jun; Vol. 44 (2), pp. 464-467. Date of Electronic Publication: 2024 Mar 18.

نوع المنشور: Case Reports; Journal Article

بيانات الدورية: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101719700 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2574-173X (Electronic) Linking ISSN: 2574173X NLM ISO Abbreviation: Neuropsychopharmacol Rep Subsets: MEDLINE

مواضيع طبية MeSH: Clonazepam*/therapeutic use , Clonazepam*/administration & dosage , Burning Mouth Syndrome*/drug therapy , Drug Therapy, Combination* , Isoindoles*/therapeutic use , Isoindoles*/administration & dosage, Humans ; Middle Aged ; Male ; Female ; Thiazoles/therapeutic use ; Thiazoles/administration & dosage ; GABA Modulators/therapeutic use ; GABA Modulators/administration & dosage

المؤلفون: Ginzac A; INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, F- 63000, France. angeline.ginzac@clermont.unicancer.fr.; Centre d'Investigation Clinique UMR501, Clermont-Ferrand, F-63000, France. angeline.ginzac@clermont.unicancer.fr.; Département de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand, F-63000, France. angeline.ginzac@clermont.unicancer.fr., Molnar I; INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, F- 63000, France.; Centre d'Investigation Clinique UMR501, Clermont-Ferrand, F-63000, France.; Département de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand, F-63000, France., Durando X; INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, F- 63000, France.; Centre d'Investigation Clinique UMR501, Clermont-Ferrand, F-63000, France.; Département de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand, F-63000, France.; Service d'oncologie médicale, Centre Jean PERRIN, Clermont-Ferrand, F-63000, France., Motte Rouge T; Service d'oncologie médicale, Centre Eugène MARQUIS, Rennes, France., Petit T; Service d'oncologie médicale, Institut de Cancérologie Strasbourg Europe, Strasbourg, France., D'hondt V; Service d'oncologie médicale, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France., Campone M; Service d'oncologie médicale, Institut de Cancérologie de l'Ouest, René GAUDUCHEAU, Saint Herblain, France., Bonichon-Lamichhane N; Service d'oncologie médicale et radiothérapie, Clinique Tivoli, Bordeaux, France., Venat Bouvet L; Service d'oncologie médicale, CHU Dupuytren, Limoges, France., Levy C; Service d'oncologie médicale, Centre François BACLESSE, Caen, France., Augereau P; Service d'oncologie médicale, Institut de Cancérologie de l'Ouest, René GAUDUCHEAU, Saint Herblain, France., Pistilli B; Service d'oncologie médicale, Institut Gustave ROUSSY, Villejuif, France., Arsene O; Service d'oncologie médicale, Centre Hospitalier de Blois, Blois, France., Jouannaud C; Service d'oncologie médicale, Institut Jean GODINOT, Reims, France., Nguyen S; Service d'oncologie médicale, Centre Hospitalier de Pau, Pau, France., Cayre A; Service d'anatomopathologie, Centre Jean PERRIN, Clermont-Ferrand, France., Tixier L; Service d'anatomopathologie, Centre Jean PERRIN, Clermont-Ferrand, France., Mahier Ait Oukhatar C; Unicancer, Paris, France., Nabholtz JM; Centre d'oncologie, Université King Saud (Medical City), Riyadh, Arabi Saoudite., Penault-Llorca F; INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, F- 63000, France.; Service d'anatomopathologie, Centre Jean PERRIN, Clermont-Ferrand, France., Mouret-Reynier MA; Service d'oncologie médicale, Centre Jean PERRIN, Clermont-Ferrand, F-63000, France.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Jun; Vol. 205 (2), pp. 267-279. Date of Electronic Publication: 2024 Mar 07.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Trastuzumab*/administration & dosage , Trastuzumab*/adverse effects , Trastuzumab*/therapeutic use , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/mortality , Breast Neoplasms*/genetics , Neoadjuvant Therapy* , Receptor, ErbB-2*/metabolism , DNA Topoisomerases, Type II*/genetics , DNA Topoisomerases, Type II*/metabolism , Docetaxel*/administration & dosage , Docetaxel*/adverse effects , Carboplatin*/administration & dosage , Carboplatin*/adverse effects , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use, Humans ; Female ; Middle Aged ; Adult ; Aged ; Cyclophosphamide/administration & dosage ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Fluorouracil/therapeutic use ; Poly-ADP-Ribose Binding Proteins/genetics ; Anthracyclines/administration & dosage ; Anthracyclines/therapeutic use ; Epirubicin/administration & dosage

SCR Protocol: FEC protocol

المؤلفون: Turan O; Chest Diseases Department, Izmir Katip Celebi University, İzmir, Turkey. onurtura@yahoo.com., Ogan N; Chest Diseases Department, Ufuk University, Ankara, Turkey., Bozkus F; Chest Diseases Department, Kahramanmaraş Sütçü Imam University, Kahramanmaraş, Turkey., Sarıoğlu N; Chest Diseases Department, Balıkesir University, Balıkesir, Turkey., Turan PA; Chest Diseases Department, Menemen State Hospital, İzmir, Turkey., Satıcı C; Chest Diseases Department, İstanbul Gaziosmanpaşa Research and Training Hospital University, Istanbul, Turkey.

المصدر: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2024 Jun; Vol. 80 (6), pp. 847-853. Date of Electronic Publication: 2024 Feb 23.

نوع المنشور: Journal Article; Comparative Study; Multicenter Study

بيانات الدورية: Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1041 (Electronic) Linking ISSN: 00316970 NLM ISO Abbreviation: Eur J Clin Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Pulmonary Disease, Chronic Obstructive*/drug therapy , Adrenergic beta-2 Receptor Agonists*/therapeutic use , Adrenergic beta-2 Receptor Agonists*/administration & dosage , Muscarinic Antagonists*/administration & dosage , Muscarinic Antagonists*/therapeutic use, Humans ; Male ; Female ; Aged ; Middle Aged ; Bronchodilator Agents/therapeutic use ; Bronchodilator Agents/administration & dosage ; Treatment Outcome ; Spirometry ; Muscarinic Agonists/therapeutic use ; Muscarinic Agonists/administration & dosage ; Delayed-Action Preparations

المؤلفون: Mutch D; Division of Gynecology Oncology, Washington University School of Medicine, St Louis, Missouri, USA., Voulgari A; Global Product Development Clinical Science, Roche Products Ltd., Welwyn Garden City, UK., Chen XM; Translational Medicine, Genentech, Inc., South San Francisco, California, USA., Bradley WH; Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Oaknin A; Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Perez Fidalgo JA; Hospital Clínico Universitario Valencia, Biomedical Research Institute INCLIVA, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Valencia, Spain., Montosa FG; Medical Oncology Department, Hospital Universitario de Jaén, Jaén, Spain., Herraez AC; Department of Medical Oncology, Hospital Universitario San Carlos, Universidad Complutense, IdISSC, Madrid, Spain., Holloway RW; Gynecologic Oncology, AdventHealth Cancer Institute, Orlando, Florida, USA., Powell MA; Division of Gynecology Oncology, Washington University School of Medicine, St Louis, Missouri, USA., Nowicka M; Translational Medicine, Genentech, Inc., South San Francisco, California, USA., Schaefer G; Molecular Oncology, Genentech, Inc., South San Francisco, California, USA., Merchant M; Translational Oncology, Genentech, Inc., South San Francisco, California, USA., Yan Y; Translational Medicine, Genentech, Inc., South San Francisco, California, USA.

المصدر: Cancer [Cancer] 2024 Jun 01; Vol. 130 (11), pp. 1940-1951. Date of Electronic Publication: 2024 Jan 30.

نوع المنشور: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/pathology , Ovarian Neoplasms*/mortality , Piperidines*/therapeutic use , Piperidines*/administration & dosage , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Neoplasm Recurrence, Local*/drug therapy , Neoplasm Recurrence, Local*/genetics , B7-H1 Antigen*/antagonists & inhibitors , B7-H1 Antigen*/genetics , Phthalazines*/therapeutic use , Phthalazines*/administration & dosage, Humans ; Female ; Middle Aged ; Aged ; Adult ; Indazoles/therapeutic use ; Indazoles/administration & dosage ; BRCA1 Protein/genetics ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/administration & dosage ; Aged, 80 and over ; Platinum/therapeutic use ; Platinum/administration & dosage ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/administration & dosage ; BRCA2 Protein/genetics ; Progression-Free Survival ; Azetidines

المؤلفون: Gatti M; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Electronic address: milo.gatti2@unibo.it., Virgili G; Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Viale P; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Pea F; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

المصدر: International journal of antimicrobial agents [Int J Antimicrob Agents] 2024 Jun; Vol. 63 (6), pp. 107177. Date of Electronic Publication: 2024 Apr 19.

نوع المنشور: Letter

بيانات الدورية: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 9111860 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7913 (Electronic) Linking ISSN: 09248579 NLM ISO Abbreviation: Int J Antimicrob Agents Subsets: MEDLINE

مواضيع طبية MeSH: Anti-Bacterial Agents*/therapeutic use , Anti-Bacterial Agents*/administration & dosage , Drug Resistance, Multiple, Bacterial* , Gram-Negative Bacterial Infections*/drug therapy , Gram-Negative Bacterial Infections*/microbiology , Cerebral Ventriculitis*/drug therapy , Cerebral Ventriculitis*/microbiology , Polymyxins*/therapeutic use , Polymyxins*/administration & dosage , Meningitis, Bacterial*/drug therapy , Meningitis, Bacterial*/microbiology , Injections, Spinal* , Aminoglycosides*/therapeutic use , Aminoglycosides*/administration & dosage, Humans ; Treatment Outcome ; Gram-Negative Bacteria/drug effects ; beta-Lactams/therapeutic use ; beta-Lactams/administration & dosage ; beta-Lactamase Inhibitors/therapeutic use ; beta-Lactamase Inhibitors/administration & dosage

المؤلفون: Mills AM; Men's Health Foundation, Los Angeles, CA, USA., Rizzardini G; Hospital Sacco, Milan, Italy; School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa., Ramgopal MN; Midway Immunology and Research Center, Fort Pierce, FL, USA., Osiyemi OO; Triple O Research Institute, West Palm Beach, FL, USA., Bogner JR; Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany., Hagins DP; Chatham County Health Department, Savannah, Georgia, USA., Paredes R; Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; IrsiCaixa AIDS Research Institute, Badalona, Spain; Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Reynes J; Department of Infectious Diseases, Montpellier University Hospital, Montpellier, France; TransVIHMI, University of Montpellier, IRD, INSERM, Montpellier, France., Rockstroh JK; Department of Medicine I, University of Bonn, Bonn, Germany., Carr A; Immunology and HIV Unit, St Vincent's Hospital, Sydney, NSW, Australia., Su FH; Merck & Co, Rahway, NJ, USA., Klopfer SO; Merck & Co, Rahway, NJ, USA., Eves K; Merck & Co, Rahway, NJ, USA., Plank RM; Merck & Co, Rahway, NJ, USA., Correll T; Merck & Co, Rahway, NJ, USA., Fox MC; Merck & Co, Rahway, NJ, USA. Electronic address: michelle.fox2@merck.com.

المصدر: The lancet. HIV [Lancet HIV] 2024 Jun; Vol. 11 (6), pp. e357-e368. Date of Electronic Publication: 2024 May 08.

نوع المنشور: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101645355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3018 (Electronic) Linking ISSN: 23523018 NLM ISO Abbreviation: Lancet HIV Subsets: MEDLINE

مواضيع طبية MeSH: HIV Infections*/drug therapy , HIV Infections*/virology , Tenofovir*/administration & dosage , Tenofovir*/therapeutic use , Tenofovir*/analogs & derivatives , Emtricitabine*/administration & dosage , Emtricitabine*/therapeutic use , HIV-1*/drug effects , HIV-1*/genetics , Pyridones*/administration & dosage , Anti-HIV Agents*/administration & dosage , Anti-HIV Agents*/therapeutic use , Heterocyclic Compounds, 4 or More Rings*/administration & dosage , Heterocyclic Compounds, 4 or More Rings*/therapeutic use , Alanine*/administration & dosage , Adenine*/analogs & derivatives , Adenine*/administration & dosage , Adenine*/therapeutic use, Humans ; Female ; Male ; Adult ; Double-Blind Method ; Middle Aged ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Piperazines/administration & dosage ; Amides/administration & dosage ; Viral Load/drug effects ; Treatment Outcome ; Drug Administration Schedule ; Deoxyadenosines ; Triazoles

المؤلفون: Ferguson L; Dr. Lana Ferguson, BHB, MBChB, DipPallMed (RA CP), FRA CP, FA ChPM, Hospice Waikato, Hamilton, New Zealand., Hooper S; Dr. Stacey Hooper, MBChB, DipPallMed (RACP), Waikato District Health Board, Hamilton, New Zealand.

المصدر: Journal of pain & palliative care pharmacotherapy [J Pain Palliat Care Pharmacother] 2024 Jun; Vol. 38 (2), pp. 153-156. Date of Electronic Publication: 2024 May 08.

نوع المنشور: Case Reports; Journal Article

بيانات الدورية: Publisher: Informa Healthcare Country of Publication: England NLM ID: 101125608 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-0539 (Electronic) Linking ISSN: 15360288 NLM ISO Abbreviation: J Pain Palliat Care Pharmacother Subsets: MEDLINE

مواضيع طبية MeSH: Lidocaine*/administration & dosage , Immune Checkpoint Inhibitors*/administration & dosage , Melanoma*/drug therapy, Humans ; Male ; Middle Aged ; Lung Neoplasms/drug therapy ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/therapeutic use ; Arthritis/drug therapy ; Anesthetics, Local/administration & dosage ; Infusions, Subcutaneous ; Quality of Life